Cover Image
市場調查報告書

酒糟:開發平台分析

Rosacea - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 192813
出版日期 內容資訊 英文 72 Pages
訂單完成後即時交付
價格
Back to Top
酒糟:開發平台分析 Rosacea - Pipeline Review, H2 2016
出版日期: 2016年10月26日 內容資訊: 英文 72 Pages
簡介

所謂酒糟是影響皮膚(有時是眼睛)的長期性的疾病,引起皮膚發紅、丘疹。症狀是臉部頻繁發紅或潮紅,皮下的小紅線,鼻子膨脹,及通常有額、下巴、臉頰的厚皮等。原因包含年齡及酒糟的家族病史。治療使用抗生素及粉刺藥。

本報告提供酒糟的治療藥的開發情形調查分析、開發中產品的概要、臨床實驗的各階段的產品概要、主要企業簡介、藥物簡介、開發中產品的最新趨勢、最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

酒糟概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

調查中的治療藥:各大學/研究機關

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

開發中的產品:各企業

調查中的產品:各大學/研究機關

治療藥的開發企業

  • Allergan Plc
  • Amorepacific Corporation
  • Delenex Therapeutics AG
  • Dermira Inc.
  • Foamix Pharmaceuticals Ltd.
  • Hovione FarmaCiencia SA
  • Merz Pharma GmbH & Co. KgaA
  • Promius Pharma, LLC
  • TWi Pharmaceuticals, Inc.
  • Valeant Pharmaceuticals International, Inc.

治療藥的評估

  • 單獨療法的情況
  • 聯合治療的情況
  • 各標靶
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介(產品說明、作用機制、R&D進展)

  • ACUD-1
  • DFD-04
  • DLX-1008
  • DRM-02
  • FMX-103
  • incobotulinumtoxin A
  • minocycline
  • omiganan pentahydrochloride
  • oxymetazoline hydrochloride
  • PAC-14028
  • PDI-320
  • SIG-990
  • tetracycline MR

開發中產品的最新趨勢

暫停的計劃

開發中止的產品

產品開發的里程碑

  • 最新消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8586IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Rosacea - Pipeline Review, H2 2016, provides an overview of the Rosacea (Dermatology) pipeline landscape.

Rosacea is a chronic and potentially life-disruptive disorder primarily of the facial skin, often characterized by flare-ups and remissions. Symptoms include frequent redness of the face, or flushing, small, red lines under the skin, a swollen nose and thick skin, usually on the forehead, chin, and cheeks. The predisposing factors include age and family history of rosacea. Treatment includes antibiotics and acne drugs.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Rosacea - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Rosacea (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Rosacea (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Rosacea and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 1, 2, 7, 3, 1 and 3 respectively for Rosacea.

Rosacea (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Rosacea (Dermatology).
  • The pipeline guide reviews pipeline therapeutics for Rosacea (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Rosacea (Dermatology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Rosacea (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Rosacea (Dermatology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Rosacea (Dermatology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Rosacea (Dermatology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Rosacea Overview
  • Therapeutics Development
    • Pipeline Products for Rosacea - Overview
  • Rosacea - Therapeutics under Development by Companies
  • Rosacea - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Rosacea - Products under Development by Companies
  • Rosacea - Companies Involved in Therapeutics Development
    • Allergan Plc
    • Amorepacific Corporation
    • Cell Medica Limited
    • Cutanea Life Sciences Inc
    • Foamix Pharmaceuticals Ltd.
    • Hovione FarmaCiencia SA
    • Merz Pharma GmbH & Co. KgaA
    • Promius Pharma, LLC
    • Sol-Gel Technologies Ltd.
    • TWi Pharmaceuticals, Inc.
  • Rosacea - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • AC-701 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ACUD-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • B-244 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • benzoyl peroxide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • brolucizumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CLS-005 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DFD-29 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DMT-200 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DMT-210 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DMT-220 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FMX-103 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • incobotulinumtoxin A - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • itraconazole - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • minocycline - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • omiganan pentahydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • oxymetazoline hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PAC-14028 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Rosacea - Dormant Projects
  • Rosacea - Discontinued Products
  • Rosacea - Product Development Milestones
    • Featured News & Press Releases
      • Sep 28, 2016: Dermata Therapeutics, LLC Announces Positive Top-line Results from their Phase 1 Pharmacokinetic Study of DMT210 in Acne Rosacea Patients
      • Sep 12, 2016: Foamix Announces Positive Topline Results from Phase 2 Trial Evaluating FMX-103 Topical Minocycline Foam for Moderate-to-Severe Papulopustular Rosacea
      • Sep 09, 2016: Foamix to Announce Topline Results in Phase 2 Clinical Trial of FMX-103 Minocycline Topical Foam for Moderate-to-Severe Papulopustular Rosacea
      • May 24, 2016: Allergan Announces FDA Acceptance of NDA Filing for Oxymetazoline HCI Cream 1.0%
      • May 19, 2016: Galderma Laboratories Announces Availability of New Mirvaso (brimonidine) Topical Gel, 0.33% Pump Dispenser for the Treatment of the Persistent Facial Redness of Rosacea
      • May 16, 2016: Dermata Therapeutics Announces Initiation of Phase 1 Pharmacokinetic Study
      • May 03, 2016: Foamix Announces Completion of Enrollment in Phase 2 Clinical Trial of Minocycline Foam (FMX103) for Treatment of Papulopustular Rosacea
      • Oct 20, 2015: Foamix Announces Enrollment of First Patient in Phase 2 Clinical Trial of FMX103 in Papulopustular Rosacea
      • Apr 17, 2014: Treatment for Facial Redness Associated With Rosacea Now Available in the UK
      • Feb 26, 2014: mirvaso the first and only treatment targeting the facial redness of rosacea approved by the european commission
      • Jan 29, 2014: Galderma Announces the Publication of Positive Results of the Long-Term Study of Mirvaso Gel for Treatment of Persistent Erythema of Rosacea
      • Dec 20, 2013: Galderma Receives CHMP Positive Opinion For Mirvaso
      • Sep 27, 2013: Galderma Announces Availability of Mirvaso (brimonidine) Topical Gel, 0.33%
      • Aug 26, 2013: Galderma Receives FDA Approval of Mirvaso
      • Jul 08, 2013: Signum Dermalogix Investigational New Drug Application Cleared by FDA: SIG990 a Potential Treatment for Rosacea
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Rosacea, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Rosacea - Pipeline by Allergan Plc, H2 2016
  • Rosacea - Pipeline by Amorepacific Corporation, H2 2016
  • Rosacea - Pipeline by Cell Medica Limited, H2 2016
  • Rosacea - Pipeline by Cutanea Life Sciences Inc, H2 2016
  • Rosacea - Pipeline by Foamix Pharmaceuticals Ltd., H2 2016
  • Rosacea - Pipeline by Hovione FarmaCiencia SA, H2 2016
  • Rosacea - Pipeline by Merz Pharma GmbH & Co. KgaA, H2 2016
  • Rosacea - Pipeline by Promius Pharma, LLC, H2 2016
  • Rosacea - Pipeline by Sol-Gel Technologies Ltd., H2 2016
  • Rosacea - Pipeline by TWi Pharmaceuticals, Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Rosacea - Dormant Projects, H2 2016
  • Rosacea - Dormant Projects (Contd..1), H2 2016
  • Rosacea - Discontinued Products, H2 2016

List of Tables

  • Number of Products under Development for Rosacea, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Rosacea - Pipeline by Allergan Plc, H2 2016
  • Rosacea - Pipeline by Amorepacific Corporation, H2 2016
  • Rosacea - Pipeline by Cell Medica Limited, H2 2016
  • Rosacea - Pipeline by Cutanea Life Sciences Inc, H2 2016
  • Rosacea - Pipeline by Foamix Pharmaceuticals Ltd., H2 2016
  • Rosacea - Pipeline by Hovione FarmaCiencia SA, H2 2016
  • Rosacea - Pipeline by Merz Pharma GmbH & Co. KgaA, H2 2016
  • Rosacea - Pipeline by Promius Pharma, LLC, H2 2016
  • Rosacea - Pipeline by Sol-Gel Technologies Ltd., H2 2016
  • Rosacea - Pipeline by TWi Pharmaceuticals, Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Rosacea - Dormant Projects, H2 2016
  • Rosacea - Dormant Projects (Contd..1), H2 2016
  • Rosacea - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Rosacea, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top